These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 24702529)
1. Management of Anemia and other Hematologic Derangements in Patients with Chronic Kidney Disease. Ansari I; Sheikh A; Ahmed SS; Jabbar Q; Ali S Arab J Nephrol Transplant; 2014 Jan; 7(1):13-9. PubMed ID: 24702529 [TBL] [Abstract][Full Text] [Related]
2. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178 [TBL] [Abstract][Full Text] [Related]
3. [Clinical management of anemia in patients with CKD]. Rivera RF; Alibrandi MTS; Di Lullo L; Fioccari F G Ital Nefrol; 2017 Mar; 34(Suppl 69):20-35. PubMed ID: 28682026 [TBL] [Abstract][Full Text] [Related]
4. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency]. Dimković N Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218 [TBL] [Abstract][Full Text] [Related]
5. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin. Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074 [TBL] [Abstract][Full Text] [Related]
6. Practical approach to the diagnosis and treatment of anemia associated with CKD in elderly. Agarwal AK J Am Med Dir Assoc; 2006 Nov; 7(9 Suppl):S7-S12; quiz S17-21. PubMed ID: 17098634 [TBL] [Abstract][Full Text] [Related]
7. Anemia Treatment by Erythropoiesis-stimulating Agents during the 6 Months before the Initiation of Hemodialysis: Comparison of Darbepoetin Alfa and Continuous Erythropoietin Receptor Activator. Yoshida T; Hayashi M Keio J Med; 2017 Sep; 66(3):44-50. PubMed ID: 27990008 [TBL] [Abstract][Full Text] [Related]
8. Methoxy Polyethylene Glycol-Epoetin Beta as a Novel Erythropoiesis Stimulating Agent with Possible Nephroprotective and Cardiovascular Protective Effects in Non-Dialysis Chronic Kidney Disease Patients. Piotr B; Mariusz S; Jacek R Curr Pharm Biotechnol; 2017; 18(4):303-308. PubMed ID: 28137221 [TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial. Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM; Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616 [TBL] [Abstract][Full Text] [Related]
10. [Impact of anemia correction on the production of the circulating morphogenetic protein α-Klotho in patients with Stages 3B-4 chronic kidney disease: A new direction of cardionephroprotection]. Milovanov YS; Mukhin NA; Kozlovskaya LV; Milovanova SY; Markina MM Ter Arkh; 2016; 88(6):21-25. PubMed ID: 27296257 [TBL] [Abstract][Full Text] [Related]
11. [Erythropoietin stimulating agents in chronic kidney disease: indications and contraindications]. Żebrowski P; Mieczkowski M Wiad Lek; 2016; 69(5):753-755. PubMed ID: 28033602 [TBL] [Abstract][Full Text] [Related]
12. Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease. Kim SM; Kim KM; Kwon SK; Kim HY J Korean Med Sci; 2016 Jan; 31(1):55-60. PubMed ID: 26770038 [TBL] [Abstract][Full Text] [Related]
13. An overview on safety issues related to erythropoiesis-stimulating agents for the treatment of anaemia in patients with chronic kidney disease. Del Vecchio L; Locatelli F Expert Opin Drug Saf; 2016 Aug; 15(8):1021-30. PubMed ID: 27149639 [TBL] [Abstract][Full Text] [Related]
14. Use of Erythropoietin-Stimulating Agents (ESA) in Patients With End-Stage Renal Failure Decided to Forego Dialysis: Palliative Perspective. Cheng HW; Chan KY; Lau HT; Man CW; Cheng SC; Lam C Am J Hosp Palliat Care; 2017 May; 34(4):380-384. PubMed ID: 26718957 [TBL] [Abstract][Full Text] [Related]
15. Iron Metabolism in Chronic Kidney Disease Patients. Honda H; Hosaka N; Ganz T; Shibata T Contrib Nephrol; 2019; 198():103-111. PubMed ID: 30991401 [TBL] [Abstract][Full Text] [Related]
16. Use of erythropoiesis-stimulating agents in patients with anemia of chronic kidney disease: overcoming the pharmacological and pharmacoeconomic limitations of existing therapies. Wish JB; Coyne DW Mayo Clin Proc; 2007 Nov; 82(11):1371-80. PubMed ID: 17976358 [TBL] [Abstract][Full Text] [Related]
17. Treatment of anemia with erythropoietin-stimulating agents in kidney transplant recipients and chronic kidney disease-another drawback of immunosuppression? Malyszko J; Glowinska I; Mysliwiec M Transplant Proc; 2012 Dec; 44(10):3013-6. PubMed ID: 23195016 [TBL] [Abstract][Full Text] [Related]
18. New Treatment Approaches for the Anemia of CKD. Bonomini M; Del Vecchio L; Sirolli V; Locatelli F Am J Kidney Dis; 2016 Jan; 67(1):133-42. PubMed ID: 26372086 [TBL] [Abstract][Full Text] [Related]
19. Pathophysiology of anemia in chronic kidney diseases: A review. Zadrazil J; Horak P Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun; 159(2):197-202. PubMed ID: 24401900 [TBL] [Abstract][Full Text] [Related]
20. Early low-dose erythropoiesis-stimulating agent therapy and progression of moderate chronic kidney disease: a randomized, placebo-controlled trial. Fliser D; Dellanna F; Koch M; Wiggenhauser A; Nephrol Dial Transplant; 2017 Feb; 32(2):279-287. PubMed ID: 28186540 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]